Overview

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2023-09-18

Target enrollment:

Participant gender:

Summary

The trial was a randomized, open-label, multicenter Phase II study of patients with advanced or metastatic NSCLC who don't harbor driver genes. The aim is to explore the efficacy and safety of Envafolimab Combined With Endostar/S-1 in second-line treatment of advanced non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Anhui Chest Hospital

Treatments:

Endostar protein
Endostatins
Tegafur